; (II) to ensure that parties will not bring a dispute under another agreement for actions that are consistent with the agreement; and (III) to provide a dispute settlement mechanism comparable to the dispute settlement provisions of the Agreement between the United States of America, the United Mexican States, and Canada. (ix) To minimize the ability of parties to the agreement to undermine the effectiveness of the agreement by abusing exceptions in the agreement by including additional procedural requirements, such as notification of intent to rely on an exception at the time an inconsistent action is taken, and limiting the duration that participants may rely on an exception. (B) Definitions In this paragraph: (i) Active pharmaceutical ingredient The term active pharmaceutical ingredient — (I) means any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of a disease, or to affect the structure or any function of the body of a human or animal; and (II) does not include— (aa) intermediates used in the synthesis of a drug product